{"id":49815,"date":"2022-10-19T17:02:54","date_gmt":"2022-10-19T15:02:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/"},"modified":"2022-10-19T17:02:54","modified_gmt":"2022-10-19T15:02:54","slug":"beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/","title":{"rendered":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project"},"content":{"rendered":"
\n

\nPowered by the BeeKeeperAI<\/i>\u2122 sightless computing platform, Novartis scientists used health data from a UCSF patient cohort to refine a disease detection solution for a rare childhood condition<\/i>\n<\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–#azure<\/a>–BeeKeeperAI, the pioneer in sightless computing on protected data, today announced that it worked with scientists from Novartis Biome\u2019s Evidence Lab and the University of California, San Francisco (UCSF) to train and validate an algorithm to predict instances of a rare childhood condition using real patient data from health records. This project marks the first time that confidential computing technology has been leveraged to support sightless computation by an algorithm against protected health information.\n<\/p>\n

\n\u201cThis project is an important milestone in the development of the rare disease solution by the Evidence Lab,\u201d said Robin Roberts, Co-founder and Chief Operating Officer at Novartis Biome. \u201cRare diseases are often challenging to diagnose and if left untreated, they can significantly diminish a patient\u2019s quality of life. With BeeKeeperAI, our scientists were able to securely access a large gold standard dataset that enabled us to improve the predictive capabilities of our algorithm, bringing us much closer to identifying patients early in the disease course and to improving their outcomes.\u201d\n<\/p>\n

\nThe Novartis Biome Evidence Lab was developed in collaboration with health systems and data providers as a space for health tech companies to test their digital solutions and identify ways to optimize and scale their offerings. BeeKeeperAI\u2019s zero trust architecture supports sightless computing of algorithms against protected information. It uses advanced encryption within secure computing enclaves to enable data stewards and algorithm developers to collaborate without exposing the data or revealing important IP. The platform eliminates reliance on data deidentification or difficult to enforce contractual agreements that typically govern access to protected health information.\n<\/p>\n

\n\u201cThe traditional mechanisms for securing permission to use confidential patient information to develop healthcare AI are time-consuming and costly and that has slowed the pace of innovation in the field. We developed our platform with an eye towards addressing the constraints of existing approaches for accessing protected information and helping algorithm developers and data stewards collaborate far more effectively,\u201d said Michael Blum, MD, Co-founder and Chief Executive Officer at BeeKeeperAI.\n<\/p>\n

\nThe Novartis project leveraged Microsoft Azure\u2019s confidential computing environment utilizing an Intel SGX secure enclave. Prior to moving the data into the secure enclave at UCSF, BeeKeeperAI worked with clinical and data science experts at UCSF to curate, harmonize, and encrypt data that included 28 pediatric patients diagnosed with the pediatric rare disease in question and an additional 2,000 matched controls. Simultaneously, BeeKeeperAI enabled the Novartis scientists to prepare the algorithm for the secure environment, including encrypting and uploading it to the BeeKeeperAI cloud platform. Encrypting both the data and the algorithm ensured that they remain protected throughout the computing process.\n<\/p>\n

\nOnce the encrypted algorithm and data were in the secure enclave, they were decrypted, and the algorithm was allowed to compute against the identifiable data. The process was fully automated and sightless. The output of the computation was a report that provided performance metrics. Novartis scientists used the feedback from the BeeKeeperAI platform to fine-tune the algorithm and rerun it against the data. Through this iterative loop, they significantly improved the predictive capabilities of their solution to detect patients with the rare condition. The solution is now ready for further validation at additional academic medical centers known for treating this rare condition.\n<\/p>\n

\nBeeKeeperAI will be participating in the Novartis Biome’s “Closing the Digital Divide: Validation through Partnership” event on Wednesday, October 19, where they will share more details of the healthcare AI project with Novartis Biome and UCSF.\n<\/p>\n

\nAbout Novartis Biome<\/b>\n<\/p>\n

\nNovartis Biome is a bridge to help partners become an extension of Novartis own teams, working with them as easily and productively as possible to jointly innovate and co-develop digital solutions at scale. The Biome is committed to partnering with the best in the ecosystem to combine deep scientific experience with the expertise of the tech world to develop \u2013 and crucially \u2013 scale digital solutions that improve and extend patients\u2019 lives. Learn more at https:\/\/www.biome.novartis.com<\/a>\n<\/p>\n

\nAbout BeeKeeperAI<\/b>\n<\/p>\n

\nBeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce. For more information, go to beekeeperAI.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Anthony Petrucci
\n
Bioscribe
\n
anthony@bioscribe.com<\/a>
512-581-5442\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Powered by the BeeKeeperAI\u2122 sightless computing platform, Novartis scientists used health data from a UCSF patient cohort to refine a disease detection solution for a rare childhood condition SAN FRANCISCO–(BUSINESS WIRE)–#azure–BeeKeeperAI, the pioneer in sightless computing on protected data, today announced that it worked with scientists from Novartis Biome\u2019s Evidence Lab and the University of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49815","6":"format-standard","7":"category-industry"},"yoast_head":"\nBeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Powered by the BeeKeeperAI\u2122 sightless computing platform, Novartis scientists used health data from a UCSF patient cohort to refine a disease detection solution for a rare childhood condition SAN FRANCISCO–(BUSINESS WIRE)–#azure–BeeKeeperAI, the pioneer in sightless computing on protected data, today announced that it worked with scientists from Novartis Biome\u2019s Evidence Lab and the University of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T15:02:54+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project\",\"datePublished\":\"2022-10-19T15:02:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/\"},\"wordCount\":760,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/\",\"name\":\"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-10-19T15:02:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/","og_locale":"en_US","og_type":"article","og_title":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend","og_description":"Powered by the BeeKeeperAI\u2122 sightless computing platform, Novartis scientists used health data from a UCSF patient cohort to refine a disease detection solution for a rare childhood condition SAN FRANCISCO–(BUSINESS WIRE)–#azure–BeeKeeperAI, the pioneer in sightless computing on protected data, today announced that it worked with scientists from Novartis Biome\u2019s Evidence Lab and the University of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-19T15:02:54+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project","datePublished":"2022-10-19T15:02:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/"},"wordCount":760,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/","url":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/","name":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-10-19T15:02:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beekeeperai-applies-sightless-computing-technology-to-pediatric-rare-disease-project\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49815"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49815\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}